{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-327097","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2025-12-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.290302+00:00","generated_at":"2026-05-16T12:36:41.852013+00:00","sec_items":["1.01","3.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"IN8bio enters $20.1M private placement with potential second $20.1M tranche tied to INB-619 milestone","bullets":["Initial closing: 5,127,029 shares at $1.38 and 9,452,677 pre-funded warrants for ~$20.1M gross.","Second closing up to 14.6M shares/warrants (~$20.1M) conditional on INB-619 milestone and stock price hitting $2.76 or waiver.","Investors granted pre-emptive rights to participate in subsequent equity financings up to 200% of their investment.","Company to file resale registration statement within 30 days of each closing, with liquidated damages for delays.","Private placement exempt from registration; purchasers are qualified institutional buyers or accredited investors."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-327097","json":"https://secwatch.observer/filing/0001193125-25-327097.json","markdown":"https://secwatch.observer/filing/0001193125-25-327097.md","text":"https://secwatch.observer/filing/0001193125-25-327097.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525327097/0001193125-25-327097-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525327097/d145007d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:36:41.852013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"43e232e20f81da5a051d010999b68b3cdecbad0d","claim":"IN8BIO, INC. issued 5,127,029 Shares of Common Stock, at a purchase price of $1.38 per Share of common stock to the Investors for aggregate gross proceeds of approximately $20.1 million.","evidence_excerpt":"to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant (the “Pre-Funded Warrant Price”) for aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses. Pursuant to the Purchase Agreement, subject to the occurrence of the Second Closing Trigger (as","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525327097/0001193125-25-327097-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"common stock"},{"label":"Shares","value":"5,127,029 Shares of Common Stock, at a purchase price of $1.38 per Share"},{"label":"Purchaser","value":"the Investors"},{"label":"Consideration","value":"aggregate gross proceeds of approximately $20.1 million"}],"fact_type":"equity_issuance"},{"claim_id":"6cca732276ecc848ffb922620fdf2e179bc415b2","claim":"IN8BIO, INC. issued Pre-Funded Warrants to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant of warrant to the Investors for aggregate gross proceeds of approximately $20.1 million.","evidence_excerpt":"At the Initial Closing, the Company has agreed to issue and sell to the Investors an aggregate of 5,127,029 Shares of Common Stock, at a purchase price of $1.38 per Share (the “Share Price”), and, in lieu of Common Stock, Pre-Funded Warrants to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant (the “Pre-Funded Warrant Price”) for aggregate gross proceeds of approximately $20.1 million, before deducting placement agent fees and other private placement expenses.","evidence_source":"SEC 8-K Item 3.02/3.03","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525327097/0001193125-25-327097-index.htm","confidence":0.95,"family_label":"Equity Issuances","details":[{"label":"Security","value":"warrant"},{"label":"Shares","value":"Pre-Funded Warrants to purchase up to 9,452,677 Warrant Shares, at a purchase price of $1.3799 per Pre-Funded Warrant"},{"label":"Purchaser","value":"the Investors"},{"label":"Consideration","value":"aggregate gross proceeds of approximately $20.1 million"}],"fact_type":"equity_issuance"},{"claim_id":"5e0324ea3740f2080cbac7fee27da588619376b6","claim":"IN8BIO, INC. entered into Securities Purchase Agreement with the purchasers named therein (the \"Investors\") valued at aggregate gross proceeds of approximately $20.1 million (effective 2025-12-18).","evidence_excerpt":"On December 18, 2025, IN8bio, Inc. (the “Company”) entered into a Securities Purchase Agreement (the “Purchase Agreement”) with the purchasers named therein (the “Investors”)","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312525327097/0001193125-25-327097-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"the purchasers named therein (the \"Investors\")"},{"label":"Value","value":"aggregate gross proceeds of approximately $20.1 million"},{"label":"Effective","value":"2025-12-18"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}